RenovoRx Inc
NASDAQ:RNXT
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
S
|
Shenzhen Success Electronics Co Ltd
SZSE:002289
|
CN |
|
C
|
Carlsberg A/S
LSE:0AI4
|
DK |
|
Relia Inc
TSE:4708
|
JP |
|
Saudi Cable Company SJSC
SAU:2110
|
SA |
|
H
|
Honasa Consumer Ltd
NSE:HONASA
|
IN |
|
Resmed Inc
NYSE:RMD
|
US |
|
Furuno Electric Co Ltd
TSE:6814
|
JP |
|
Wereldhave Belgium NV
XBRU:WEHB
|
BE |
RenovoRx Inc
Total Current Assets
RenovoRx Inc
Total Current Assets Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Current Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
RenovoRx Inc
NASDAQ:RNXT
|
Total Current Assets
$7.9m
|
CAGR 3-Years
3%
|
CAGR 5-Years
33%
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Total Current Assets
$29.1B
|
CAGR 3-Years
1%
|
CAGR 5-Years
4%
|
CAGR 10-Years
6%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Total Current Assets
$18.3B
|
CAGR 3-Years
8%
|
CAGR 5-Years
3%
|
CAGR 10-Years
-3%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Total Current Assets
$29.1B
|
CAGR 3-Years
9%
|
CAGR 5-Years
7%
|
CAGR 10-Years
-3%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Total Current Assets
$11.2B
|
CAGR 3-Years
-5%
|
CAGR 5-Years
7%
|
CAGR 10-Years
23%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Total Current Assets
$18B
|
CAGR 3-Years
4%
|
CAGR 5-Years
13%
|
CAGR 10-Years
20%
|
|
RenovoRx Inc
Glance View
RenovoRx, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for the local treatment of solid tumors. The company is headquartered in San Jose, California and currently employs 6 full-time employees. The company went IPO on 2021-08-17. The firm is focused on developing therapies for the local treatment of solid tumors. The firm's lead product candidate RenovoGem. Its other product candidate include Renovo Trans-Arterial Micro-Perfusion (RenovoTAMP), and RenovoCath delivery system. RenovoGem, is a drug and device combination consisting of intra-arterial gemcitabine and RenovoCath. Its therapy platform, RenovoRx Trans-Arterial Micro-Perfusion (RenovoTAMP) is focused on optimizing drug concentration in solid tumors using small molecule chemotherapeutics that enable physicians to isolate segments of the vascular anatomy closest to tumors and force chemotherapy across the blood vessel wall to bathe these difficult-to-reach tumors in chemotherapy.
See Also
What is RenovoRx Inc's Total Current Assets?
Total Current Assets
7.9m
USD
Based on the financial report for Dec 31, 2025, RenovoRx Inc's Total Current Assets amounts to 7.9m USD.
What is RenovoRx Inc's Total Current Assets growth rate?
Total Current Assets CAGR 5Y
33%
Over the last year, the Total Current Assets growth was 1%. The average annual Total Current Assets growth rates for RenovoRx Inc have been 3% over the past three years , 33% over the past five years .
